Chinese drug regulation authorities have approved Swiss pharmaceutical firm Novartis AG's drug Sebivo, a brand name for telbivudine, as a treatment for chronic hepatitis B in February 2007. The decision comes shortly after Sebivo was recommended for approval in the European Union.
Chinese drug regulatory authorities approved Novartis AG's drug Sebivo (telbivudine), a medication for chronic hepatitis B, in February 2007. This approval followed the European Union's recommendation for Sebivo to be used in treating chronic hepatitis B.